sensitivity of 41.5% (95%CI 27.8-56.6%) and a specificity of 91.1% (95%CI 88.4-27
93.2%) for predicting 30-day MACE. 28 29
Conclusion A modified TIMI score of 0 or a HEART score of ≤2, incorporating a 30 single hs-cTnT level, will identify patients with low risk of 30-day MACE for early 31 discharge within 2 hours of ED arrival. 32 H-FABP is thought to be superior to creatine kinase-MB or cardiac troponins in early 62 detection of ischemic myocardial necrosis. [18] 63
In this study we aimed firstly to validate an early TIMI score with hs-cTnT to rule out 64 30-day MACE, and secondly to compare this with H-FABP, a modified HEART 65 score and their combined use. Applying this protocol in clinical practice has the 66 potential to reduce ED waiting times, ED crowding and hospital admission rates for 67 chest pain patients. This is a sub-study of a prospective observational study of adult 68 patients with potentially cardiac chest pain who underwent computer tomography (CT) 69 scan to evaluate the usefulness of coronary calcium score in risk-stratifying chest pain 70
patients. 71 72

METHODS 73
Study design 74
We conducted a prospective study between 4 March 2013 and 31 March 2014 in the 75 ED of a tertiary referral university hospital in Hong Kong. The study is registered 76 with ClinicalTrials.gov (no. NCT02364271). Ethical approval was obtained from the 77 joint Institutional Review Board of the Chinese University of Hong Kong and Prince 78
The study included consecutive eligible patients presenting to the ED from 9am to 86 4pm from Monday to Friday. We included patients who had chest or epigastric pain 87 within 24 hours prior to ED presentation, and symptoms suggestive of cardiac chest 88 pain, and for whom hs-cTnT measurement was requested by the assessing emergency 89 physician. Patients were excluded if STEMI or ACS was confirmed immediately on 90 ED arrival, or if there was hemodynamic instability, pregnancy, under the age of 18, 91 or unable to obtain informed consent. Data collection commenced at triage. The 92 funding for this study involved ED assessments for the role of CT calcium scoring to 93 rule in ACS and MACE so we excluded patients if they had a pacemaker or any 94 metal device implantation, or if there was previous coronary artery bypass grafting 95 (CABG) or percutaneous coronary intervention (PCI). With this exclusion criteria and 96 the recruitment in less than 8 hours a day and in working days only, the number of 97 subjects included is not very high. Only one patient was lost in the 30 day telephone 98 follow-up and was excluded from the analysis. 99
Measurements 100
Data collected by research staff included patient characteristics, medical history, 101
conventional risk factors and current medication. An ECG and serial hs-cTnT 102 (Elecsys® Troponin T hs, Roche Diagnostics, Germany, upper reference limit (99thpatient was unsure of an answer to a question (e.g. family history of cardiac disease). 111
Serial hs-cTnT measurements were performed when assessing physician decided it 112 was necessary to confirm the diagnosis. Assessing physicians adjudicated the final 113 diagnosis independently without reference to the scoring charts and the diagnosis was 114 reviewed, also without reference to the charts, by the study investigator to ensure 115 compliance with the Third Universal Definition of Myocardial Infarction. [22] We 116 retrieved follow-up data, including subsequent visits to ED, hospital readmission for 117 evaluation of chest pain and all cardiac procedures, from the hospital authority's 118 computerized medical system (CMS) and verified them via telephone follow-up at 30 119 days after initial presentation. We also obtained information about death, myocardial 120 infarction, readmission for ACS, and all cardiac testing and coronary 121 revascularization procedures, whether in our hospital or other hospitals from the CMS 122 and the telephone follow ups. Research staffs collecting this data were not blinded 123 from the ED data. 124
Definitions 125
MACEs include the condition at initial hospital presentation and subsequent events 126 within 30 days, and encompass both safety and effectiveness elements. Safety 127 outcomes consist of all-cause mortality (including cardiac death), cardiac arrest, 128 myocardial infarction and cardiogenic shock. Effectiveness outcomes consist of 129 revascularization (e.g. coronary artery bypass grafting or percutaneous coronary 130 intervention), ventricular arrhythmia needing intervention and high-degree 131 atrioventricular block needing intervention. [21] 
TIMI and modified HEART Scores 145
We considered a TIMI score of 0 as low risk for 30-day MACE. We defined a 146 negative initial hs-cTnT result as a concentration of ≤14ng/L. We considered a 147 modified HEART score ≤2 as low risk for 30-day MACE. Modified from the original 148 HEART score, only the presence of ST-deviation of >0.05mV was considered in the 149 initial ECG result which scored one point. We used initial measurement of hs-cTnT as 150 the biomarker in the score. 151
Primary Outcome 152
The primary outcome was the number of patients with one or more MACE within 30 153 days of initial ED presentation, including the diagnosis of initial ED presentation. 154
Statistical analysis 155
We showed baseline characteristics of the study population as conventional 156 descriptive statistics. Median and interquartile range are reported (IQR Table 1 shows the baseline characteristics of all patients with and without 30-172 day MACE. A MACE occurred in 42 (7.0%, 95%CI: 5.1% to 9.2%) patients. 173 16 (2.7% 95%CI:1.6-4.2%) patients had NSTEMI and 11 (1.8% 95%CI:1.0-174 3.2%) had STEMI. 26 (4.3% 95%CI:2.8-6.3%) patients had emergency 175 revascularization. 5 (0.8% 95%CI:0.3-1.9%) deaths were recorded. 176 Table 2 shows the predictive accuracy of the TIMI and HEART scores, initial 177 hs-cTnT test and initial ECG, and H-FABP for the prediction of MACE within 30 178 days. A negative ECG result alone gave 23 false negative results. This reduced to 3 179 with the addition of hs-cTnT, and further reduced to zero false negatives when TIMI 180 or the modified HEART scores were used. Initial H-FABP concentration ≤7g/L 181 alone resulted in 24 false negative cases when used as a rule-out tool. In data not 182 shown, addition of H-FABP to TIMI or HEART score did not improve the 183 performance of the scores.
Combining TIMI>0 and mHEART>2 identified 479 (80%, 95% CI 76-83%) 185 patients to be high risk and suggested longer observation while 498 (83%, 95%CI 79-186 86%) patients in the current setting had a second hs-cTnT measurement. 187 188
DISCUSSION 189
The purpose of our study was to evaluate various combinations of risk-assessment 190 tools for the early and safe discharge of patients. There is no recommended 191 sensitivity level which has universal acceptance for acceptable safety in this context, 192 although it is appreciated that no test or protocol can achieve absolute safety. We 193 have set a point sensitivity of >99% as an essential parameter for selecting an 194 appropriate rule-out tool. Once this level is achieved then we have aimed for optimal 195 specificity thus allowing a maximum number of patients for safe early discharge. 196
Having set these criteria, we evaluated eight different combinations (see Table 2 ). Of 197 these combinations, only TIMI, HEART and combined TIMI/HEART achieved a 198 sensitivity >99%. The combined tool would allow the safe early discharge of 35 199 patients who were admitted under the current chest pain protocol of our hospital, 200 6.3% of the 560 patients with no evidence of 30-day MACE, a relative increase of 201 75% compared with TIMI alone, and a 46% increase compared with using HEART 202 alone. Specificity of the combined tool increased as compared with TIMI or 203 mHEART scores alone and the improvement was more prominent for TIMI score 204 with no overlap in 95% confidence interval. We also examined the c-statistics of 205 various combination of TIMI and HEART score and their components and found that 206 TIMI and HEART scores together achieved higher c-statistics than the individual tests 207 alone.
[26] Whether this potential benefit is worthwhile is debatable as the staff time 208
saved by early discharge of these patients must be weighed up against the fact that all 209 patients will require a system for accurate TIMI and/or HEART assessment at triage.This study shows that both a TIMI and modified HEART score, incorporating the 211 initial result of hs-cTnT and ECG, identifies patients with chest pain for safe 212 discharge within 2 hours of arrival. If both TIMI=0 and HEART≤2 are used to 213 classify patients as low-risk, there is a further increase in specificity and with no loss 214 in sensitivity compared with using either score alone. A 1 st hs-cTnT alone, 1 st ECG 215 alone, combined 1 st hs-cTnT/ECG, and 1 st H-FABP yielded high specificity, and may 216 be useful to rule in 30-day MACE, but their sensitivity was less than 95%, and so not 217 suitable to identify patients for early discharge. 218
The findings in our study are similar to those in ASPECT but with important 219 differences.
[4] The TIMI score incorporated a single hs-cTnT result, and with a cut 220 off of 0, yielded a sensitivity of 100% for 30-day MACE and a specificity of 12%, 221 which was similar to other studies. Score≤1, has a potential to allow early discharge of 40% of patients with suspected 225 ACS with a sensitivity for identifying AMI of 98.8%.
[27] The modified Goldman 226 Score≤1 allows for a higher percentage of early discharge than our protocol, but it 227 includes more presenting symptoms relating to the perception of pain than TIMI or 228 HEART score and the mean age of patients in our study is 8 years older than their 229 patient group, it may worth further study for the performance of these scores in 230 elderly patient groups whose interpretation of pain may be less accurate. The other 231 study also showed that, with single hs-cTnT result incorporated, TIMI score equals 0 232
and HEART score≤2 achieved a sensitivity of 100% and 98.7%, and a specificity of 233 35.0% and 14.1% respectively.
[28] A study by Santi et al. found that a HEART scoreday MACE.
[29] The sensitivities achieved are similar to our study while the higher 236 specificities may again be due to younger patient groups in their studies. Different 237 from these three studies, our study included all-cause mortality, suggesting that the 238 combination of TIMI equals 0 and HEART score≤2 is not only safe for discharge 239 without MACE within 30 days. Adding H-FABP POCT did not improve specificity 240 compared with hs-cTnT. 241
Limitations 242
This study has a number of limitations. Firstly, modifications were made to both 243 TIMI and HEART scores based on cut off criteria for hs-cTnT applied within our 244 institution. However, this is to be expected as newer markers emerge. Secondly, this 245 is a single centre study and patients who had stents or metal device implanted, or 246 underwent coronary artery bypass grafting were excluded, giving a low MACE rate 247 and wide confidence intervals in the accuracy measures. Nevertheless, these 248 sensitivity results of TIMI=0 and HEART≤2 are very similar to the findings by 249
Carlton et al. [28] Thirdly, the exact reason for admission is not always clear. Of the 250 286 patients admitted to hospital who had no MACE at 30 days, the combined scores 251 tool could have prevented 35 (12.2%, 95%CI 8.8-16.4%) admissions, and an 252
In conclusion, we have found that TIMI and a modified HEART score alone and in 260 combination, incorporating a single initial result of hs-cTnT and ECG, may be used to 261 safely identify patients with low risk of 30-day MACE for early discharge. The 262 strategy yielding the largest number of patients for safe discharge is a combined 263 modified TIMI/HEART assessment including hs-cTnT. H-FABP provided no 264 additional prognostic value to the scores as a rule-out tool. event. mHEART=modified HEART score. 'TIMI/mHEART' means either TIMI or 386 mHEART or both 387 *The family history of cardiac disease in 36 patients was unclear and so were taken as 388 'no family history of cardiac disease'. 389
